ABSTRACT
INTRODUCTION
One of the top 10 causes of death in the US is drug induced toxicity that results in substantial health care costs. 1 Mortality due to acute kidney failure is estimated at about 40 to 80% and is constantly rising while mortality due to acute myocardial infarction is decreasing worldwide. 2 Kidney failure occurs when the kidneys cannot function properly. This results in buildup of waste and fluid in the body. Acute kidney failure may develop suddenly due to drugs or other reasons. Chronic kidney failure develops gradually over years. End-stage kidney disease causes anemia, high blood pressure, bone disease, heart failure, and poor mental functioning. 3 Acute kidney failure caused by nephrotoxic drugs is estimated at around 19 to 25% of critically ill patients. These drugs injure kidney either by their hemodynamic effect, direct cellular toxicity, osmotic cellular damage, precipitation/crystallization or interstitial damage. The need for diagnostic tools to identify drug induced nephrotoxicity has been emphasized by the International Conference on Harmonization (ICH) regulated agencies. 4 In addition to this, transport mechanism is important in understanding renal drug clearance, which is sum of rates of glomerular filtration and tubular secretion minus the rate of tubular reabsorption. 5 Role of transporters in absorption, distribution, metabolism and excretion (ADME) is very important. Elimination of drugs is directly related to the uptake rate mediated by transporters. Pharmacological or toxicological effect depends on transport of drugs to and from the tissue. 6 The ATP-binding cassette (ABC) transporters are major membrane proteins involved in transport of drugs across biological membranes. These proteins dictate the reabsorptive and excretory capacity of the kidneys. 7 The multidrug resistance associated protein 1 (MRP1), a member of the ATP-binding cassette family, plays an important role in modulating the absorption, distribution, metabolism, excretion and toxicity of drugs. 7 Medications are a major source of acute kidney injury, especially in critically ill patients. Two cases where CYP deficiencies could have played an important role in acute kidney injury have been reported by Leung, Nelson et al. They performed genetic testing of their patients for the detection of CYP polymorphism. 8 The food and drug administration (FDA) made it mandatory in the USA to indicate CYP2C19*2 allele frequencies for different populations in medication guides highlighting the fact that the effectiveness of the drug varies among patients. 9 The metabolism and elimination of many drugs is mediated the enzyme cytochrome P450 2C19 (CYP2C19) which is an isoenzyme of the cytochrome P450 super family. 10 The clinical impact of the CYP2C19 of the enzyme depends on if a drug is activated or inactivated by it. Involvement of metabolic pathways and other nongenetic factors like other medicines taken can also influence the pharmacological/toxicological outcome.
10
The involvement of enzyme in drug clearance depends on the structure of the site of metabolism that allows it to select and bind with the drugs. Its substrate and inhibitor profile depends on the amino acids that shaped the substrate binding cavities.
11
Glomerular filtration, tubular secretion and tubular reabsorption are the three major processes by which drugs get eliminated via the kidney. Tubular secretion and reabsorption involve both passive and active transport processes across the membranes. Drug filtration is a diffusional passive process. The tubular secretion of drugs is mediated by many active transporters, which take up compounds from the kidney interstitium and efflux them into the tubular lumen. Organic anion transporters (OATs) and organic cation transporters (OCTs) are the two major classes of uptake transporters, but OCTNs and OATPs can also be found in the kidney. Efflux transporters, such as P-glycoprotein and MRPs are also found in the kidney tubule.
Cytochrome P450 enzymes are present in many mammalian organs, such as kidneys, lungs and intestines with the majority in the liver. 12 
MGMJMS
Drugs suspected to cause both acute renal failure as well as chronic renal failure where death has been reported as patient outcome were found to be azathioprine, clozaril/clozapine, diclofenac sodium, diflucan/ fluconazole, furosemide, indomethacin, metformin, micardis/telmisartan, viread/tenofovir, and zyprexa/ olanzapine.
Common proteins are involved in pharmacological actions for all the ten drugs.
Some observations on the ten drugs reported to cause death due to kidney failure as suspected ADR from the drug bank 16 database are as follows:
• All drugs contain N atom in their chemical formula.
• This docking study followed the rough docking protocol, which is fast with their population size of 150 with the number of generated solution = 1. The generation number was maintained at 70.
RESULTS

Identification of pocket size:
To begin with, the coordinate files of cytochrome 450 in wild and mutant state was considered for docking. But before that, the active site was identified using POCASA 1.0 the volume of the cavities were 412Å 3 , 48Å 3 and 30Å 3 in wild type (4GQS). Next, the multidrug resistant protein (2CBZ) shows a pocket size of 70Å 3 . Thus, there is a reduced pocket cavity observed in multidrug resistant protein which may not allow the binding of the drugs in to the pocket. But a better understanding of this could be only possible through docking studies. The overall active site cavity of 4GQS and 2CBZ is shown in (Figs 1A and B) . Protein-ligand docking: Docking studies were instigated using iGEMDOCK software. Both wild (4GQS) and the MDR CYP450 (2CBZ) were considered as the receptor proteins. In addition to this, the downloaded drugs were targeted against these receptors through rigid docking methods. Here all the selected ligands will be docked against the warfarin and ATP binding site of wild and DR receptors respectively.
Residual interactions: For MRP1, even though it showed lesser binding scores for drugs azathioprine, indomethacin, diflucan and furosemide. But still, they are not able to interact within the pocket, leaving it empty during docking studies. Residual interactions between mutant protein 2CBZ MRP1 and drugs are shown in Table 2 . Figure 2B shows the surface structure of the cavity after docking with protein 2CBZ with their active During this study, the wild type protein cytochrome P450 showed better interactions with drug indomethacin with a maximum score of -119.2 kcal/mol followed by drug clozaril with a score of -102.5 kcal/mol. This was finally followed by of drug zyprexa with a score of -101.0 kcal/mol. The residues which are actively involved with the drug Indomethacin include Arg97 and Arg433. This was followed by drug clozaril which shows interaction with Ala297. For drug Zyprexa the residues Arg97, Ala297 and Cys435 interact with the protein. Residual interactions between wild protein cytochrome and all the drugs is shown in Table 2 . For the wild protein, drugs with binding affinities ranges between -60 and -90 kcal/ mol are metformin, furosemide, diclofenac, diflucan and azathioprine. Drugs with binding affinities ranges between -91 and -120 kcal/mol are zyprexa, clozaril and indomethacin. Micardis with score of positive 1267.4 kcal/mol is a nonbinding drug and an outlier.
Surface structure of the active site cavity of CYP 450 2C19 with interfacial residues in red color and noninterfacial residue in soluble domain (in green color) is shown in Figure 2A . The functional site as predicted by SPPIDER http://sppider.cchmc.org/ 21 showing solvent accessibility based protein-protein interface identification and recognition of the iGEMDOCK predicted residues is shown in Table 3 with the coloring same as Figure 2A .
The surface structure of the active site of the protein MRP1 (2CBZ) with bound ATP molecule is shown in Figure 2B . The red color denotes negative residues, blue color positive residues and white color neutral residues.
DISCUSSION
Drugs with reported kidney failure associated with mortality is due to protein like 'cytochrome p450 2c19'. In the present study, docking studies showed some interesting binding patterns in the protein. For wild type, drugs like clozaril (clozapine), indomethacin and zyprexa (olanzapine) showed better binding scores due to larger binding site. However, in MDR, due to smaller cavity, all these drugs could not bind effectively. This study has shown that the increase in volume or size of cavity allows drugs to bind with a better binding score compared to the smaller cavity. With better binding, the active site gets blocked, hence the toxicity increases. The compounds with better binding score exhibits higher binding energy and more hydrogen bonds are the potential inhibitors of the enzyme cytochrome which agrees with the previous report. 22 If the binding is strong the active site is blocked, hence the toxicity increases. The compounds which have a high binding score, high binding energy and have more hydrogen bonds are the best inhibitors of the enzyme CYP2C19 which agrees with the previous report. 22 More studies are needed to further understand the role that cytochrome P450 plays in renal injury. 
